Prevention of infection in solid organ transplant receptors;Prevencion de la infeccion en receptores de trasplante de organo solido

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 15, Issue SUPPL. 2, 1997, Pages 77-89

  Lumbreras, Carlos ^a,b   Otero, Joaquín R ^a   Aguado, José M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; COTRIMOXAZOLE; FLUCONAZOLE; GANCICLOVIR; NORFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; ANTIINFECTIVE AGENT;

BACTERIAL INFECTION; HUMAN; INFECTION; MYCOSIS; ORGAN TRANSPLANTATION; PARASITOSIS; PROPHYLAXIS; REVIEW; SPAIN; VIRUS INFECTION; DISEASE TRANSMISSION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; METHODOLOGY; POSTOPERATIVE COMPLICATION; PREMEDICATION; RISK FACTOR; TRANSPLANTATION;

ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; INFECTION CONTROL; MYCOSES; PARASITIC DISEASES; POSTOPERATIVE COMPLICATIONS; PREMEDICATION; RISK FACTORS; TRANSPLANTATION; VIRUS DISEASES;

EID: 0030912954     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (156)

1. Rubin RH. Infection in the organ transplant recipient. En: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host, 3a. ed. Nueva York: Plenum Press, 1994; 629-705.
2. Rubin RH, Tolkoff-Rubin NE. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother 1993; 37: 619-624.
3. Kontoyiannis DP, Rubin RH. Infection in the organ transplant recipient. An overview. Infect Dis Clin North Am 1995; 9: 811-822.
4. Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991; 324: 1.057-1.059.
5. Hopkins C, Weber DJ, Rubin RH. Invasive aspergillus infection: possible non-ward common source within the hospital enviroment. J Hosp Infect 1989; 12: 19-25.
6. Rubin RH. The compromised host as sentinel chicken. N Engl J Med 1987; 317: 1.151-1.153.
7. Gottesdiener KM. Transplanted infections: donor to host transmission with the allograft. Ann Intern Med 1989; 110: 1.001-1.016.
8. Arnow PA, Furmaga K, Flaherty JP, George D. Microbiological efficacy and pharmacokinetics of prophylactic antibiotics in liver transplant patients. Antimicrob Agents Chemother 1992; 36: 2.125-2.130.
9. Cuervas-Mons V, Martínez AJ, Deckerr A, Starzl TE, Van Thiel DH. Adult liver transplantation: An analysis of the early causes of death in 40 consecutive cases. Hepatology 1986; 6: 495-501.
10. Dummer JS, Hardy A, Poorsattan A, Ho M. Early infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplantation 1983; 36: 259-267.
11. Paya CV, Hermans PE. Bacterial infections after liver transplantation. Eur J Clin Microbiol Infect Dis 1989; 8: 499-504.
12. Tillegard A. Renal transplant wound infection: the value of prophylaxis antibiotic treatment. Scand J Urol Nephrol 1984; 18: 215-221.
13. Townsend TR, Rudolf LE, Westervelt FB. Prophylactic antibiotic therapy with cefamandole and tobramycin for patients undergoing renal transplantation. Infect Control 1980; 1: 93-96.
14. Brooks RG, Hofflin JM, Jamieson SW, Stinson EB, Remington JS. Infectious complications in heart-lung transplant recipients. Am J Med 1985; 79: 412-422.
15. Lumbreras C, Fernández I, Velosa J, Munn S, Sterioff S, Payá CV. Infectious complications following pancreas transplantation: incidence, microbiological and clinical characteristics and outcome. Clin Infect Dis 1995; 20: 514-520.
16. Torre-Cisneros J, Villanueva JL. Infecciones bacterianas. En: Cuervas-Mons V, del Castillo Olivares JL, eds. Introducción al trasplante de órganos y tejidos. Madrid: Editorial ELA, 1994; 333-341.
17. Dauber JH, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med 1990; 11: 291-305.
18. Bubak ME, Porayko MK, Krom RA, Wiessner RH. Complications of liver biopsy in liver transplant patients: increased sepsis asociated with choledchojejunostomy. Hepatology 1991; 14: 1.063-1.065.
19. Arnow PM. Prevention of bacterial infection in the transplant recipient. The role of selective bowel decontamination. Infect Dis Clin North Am 1995; 9: 849-862.
20. Wells CL, Maddaus MA, Simmons RL. Proposed mechanisms for the translocation of intestinal bacteria. Rev Infect Dis 1988; 10: 958-979.
21. Hamer DH, Barza M. Prevention of hospital-acquired pneumonia in criticallt ill patients. Antimicrob Agents Chemother 1903; 37: 931-938.
22. Driks MR, Craven DE, Celli BR, Manning M, Burke RA, Garvin GM. Nosocomial pneumonia in intubated patients given sucralfate as compared with antiacids or hystamine type 2 blockers: the role of gastric colonization. N Engl J Med 1987; 317: 1.376-1.382.
23. Van der Waaij D. Colonization resistance of the digestive tract: clinical consequences and implications. J Antimicrob Chemother 1982; 10: 263-267.
24. Guiot HFL, van der Meer JWM, van Furth R. Selective antimicrobial modulation of human microbial flora: infection in patients with decreased host mechanisms by selective elimination of potentially pathogenic bacteria. J Infect Dis 1981; 143: 644-654.
25. Selective Decontamination of the Digestive Tract Trialists Collaborative Group. Metaanalysis of randomized controlled trials of selective decontamination of the digestive tract. Br Med J 1993; 307: 525-532.
26. Soriano G, Guaner C, Teixidó M, Such J, Barrios J, Enriquez J et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. Gastroenterology 1991; 100: 477-481.
27. Tetteroo GWM, Wagenvoort JHT, Castelein A. Tilanus HW, Ince C, Bruining HA. Selective decontamination to reduce gram negative colonization and infections after esophageal resection. Lancet 1990; 335: 704-707.
28. Taylor ME, Oppenheim BA. Selective decontamination of the gastrointestinal tract as an infection control measure. J Hosp Infect 1991; 17: 271-278.
29. Wiessner RH. Selective bowel decontamination for infection prophylaxis in liver transplantation patients. Transplant Proc 1991; 23: 1.927-1.928.
30. Kusne S, Dummer JS, Singh N, Iwatsuki S, Makowka L, Esquivel C et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine (Baltimore) 1988; 67: 132-143.
31. Payá CV, Hermans PE, Washington II JA, Smith TF, Anhalt JP, Wiesner RH et al. Incidence, distribution, and outcome of episodes of infections in 100 orthotopic liver transplantation. Mayo Clin Proc 1989; 64: 555-564.
32. George DL, Arnow PM, Fox AS, Baker AL, Thistlewhaite JR, Emond JC et al. Bacterial infection as a complication of liver transplantation. Rev Infect Dis 1991; 13: 387-396.
33. Colonna JO, Winston DJ, Brill JE, Goldstein LI, Hoff MP, Hiatt JR et al. Infectious complications in liver transplantation. Arch Surg 1988; 123: 360-364.
34. Cuervas-Mons V, Barrios C, Garrido A, Escartin P, Arcas M, Portero F et al. Bacterial infections in liver transplant patients under seletive decontamination with norfloxacin. Transplant Proc 1989; 21: 355-358.
35. Lumbreras C, Lizasoain M, Moreno E, Aguado JM, Gómez R, García I et al. Major bacterial infections following liver transplantation. A prospective study. Hepatogastroenterology 1992; 39: 362-365.
36. Arnow PM, Carandang GC, Zabner R, Irwin ME. Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Clin Infect Dis 1996; 22: 997-1.003.
37. Bion JF, Badger Y, Crosby HA, Hutchings P, Kong KL, Baker J et al. Selective decontamination of the digestive tract reduces gram-negative pulmonary colonization but not systemic endotoxemia in patients undergoing elective liver transplantation. Crit Care Med 1994; 22: 40-49.
38. Smith SD, Jackson RJ, Hannakan CJ, Wadowsky RM, Tzakis MI. Selective decontamination in pediatric liver transplants: a randomized prospective study. Transplantation 1993; 55: 1.306-1.309.
39. Gorensek MJ, Carey WD, Washington II JA, Vogt DP, Broughan TA, Westveer MK. Selective bowel decontamination with quinolones and nystatin reduces gram-negative and fungal infections in orthotopic liver transplant recipients. Cleve Clin J Med 1993; 60: 139-144.
40. Cockerill FR III, Muller JR, Anhalt JP, Marsh HM, Farnell MB, Mucha P et al. Prevention of infection in critically ill patients by selective decontamination of the digestive tract. Ann Intern Med 1992; 117: 545-553.
41. Carratalá J, Fernández-Sevilla A, Tubau F, Domínguez MA, Gudiol F. Emergence of fluorquinolone resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996; 40: 503-505.
42. Patel R, Badley AD, Larson-Keller J, Harmsen WS, Ilstrup DM, Wiessner RH et al. Relevance and risks factors of enterococcal bacteremia following liver transplantation. Transplantation 1996; 61: 1.192-1.197.
43. Patel R, Cockerill FR III, Porayko MR, Osmon D, Ilstrup D, Heating M. Lactobacillemia in liver transplant recipients. Clin Infect Dis 1994; 18: 207-212.
44. Tolkoff-Rubin NE, Cosimi AB, Russell PS, Rubin RH. A controlled study of trimethoprim-sulfametoxazole prophylaxis of urinary tract infections in renal transplant recipients. Rev Infect Dis 1982; 4: 614-618.
45. Hibberd PL, Tolkoff-Rubin NE, Doran M, Delvecchio A, Dienstag W, Katkov W et al. Trimethoprim-sulfametoxazole compared with ciprofloxacin for the prevention of ruinary tract infection in renal transplant recipients: a double-blind, randomized controlled trial.
46. Quinibi WT, Al-Sibai MB, Taher S, Harder EJ, De Vol E, Al Furayh O et al. Mycobacterial infection after renal transplantation-report of 14 cases and review of the literature. Q J Med 1990; 77: 1.039-1.060.
47. Stoblen F, Neuhaus R, Neumann K, Grauhaum O, Bechstein WO, Klein E et al. Tuberculosis in liver transplant recipients: recurrence after transplantation? Transplant Proc 1994; 26: 3.604-3.605.
48. Aguado JM, Herrero JA, Gavaldá J, Torre-Cisneros J, Blanes M, Rufi G et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipient. Transplantation 1997. En prensa.
49. Muñoz P, Palomo J, Muñoz R, Rodríguez-Creixems M, Pelaez T, Bouza E. Tuberculosis in heart transplant recipients. Clin Infect Dis 1995; 21: 398-402.
50. Moreno S, Baraia J, Bouza E, Parras F, Pérez-Tascón M, Miralles P et al. Risk for developing tuberculosis among anergic patients infected with HIV. Ann Intern Med 1989; 119: 194-198.
51. Torre-Cisneros J, De la Mata M, Rufián S, Villanueva JL, Gutiérrez J, Casai M et al. Importance of surveillance mycobacterial cultures after liver transplantation. Transplantation 1995; 60: 1.054-1.055.
52. Wajszczuk CP, Dummer JS, Ho M, Van Thiel DH, Starzl TE, Iwatsuki S et al. Fungal infections in liver transplant recipients. Transplantation 1985; 40: 347-353.
53. Castaldo P, Stratta RJ, Wood RP, Markin RS, Patil KD, Shaefer MS et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991; 126: 149-156.
54. Paya CV. Fungal infections in solid organ transplantation. Clin Infect Dis 1993; 16: 677-688.
55. Berenguer J, Allende MC, Lee JW, Garrett K, Lyman C, Ali NM et al. Pathogenesis of pulmonary aspergillosis. Granulocytopenia versas cyclosporine ans methylprednisolone-induced immunosupresion. Am J Respir Crit Care Med 1995; 152: 1.079-1.086.
56. Collins LA, Samore MH, Roberts MS et al. Risk factors for invasive fungal infections complicating liver transplantation. J Infect Dis 1994; 170: 644-652.
57. Hofflin JM, Ptsman I, Baldwin JC, Oyer PE, Stinson EB, Remington JS. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med 1987; 106: 209-216.
58. Kim JH, Perfect JR. Infection and cyclosporine. Rev Infect Dis 1989; 11: 677-690.
59. Bach MC, Adker JL, Breman J, Peng FK, Sahyoun A, Schelesinger RM. Influences of rejection therapy on fungal and nocardial infections in renal transplant patients. Lancet 1973; 1: 180-184.
60. Snydman DR, Werner BG, Dougherty NN, Griffith J, Rubin RH, Dienstag JL et al. Cytomegalovirus immuneglobulin prophylaxis in liver transplantation. A randomized, double blind, placebo controlled trial. Ann Intern Med 1993; 119: 984-991.
61. Wagner JA, Ross H, Hunt S, Gamberg P, Valantine H, Merigan TC et al. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation. Transplantation 1995; 60: 1.473-1.477.
62. Meunier F. Prevention of mycoses in immunocompromised patients. Rev Infect Dis 1987; 9: 408-417.
63. Bodey GP, Vartivarian S. Aspergillosis. Eur J Clin Microbiol Infect Dis 1989; 8: 413-437.
64. Loire R, Tabib A, Bastien O. Fatal aspergillosis after cardiac transplantation. About 26 cases. Ann Pathol 1993; 13: 157-163.
65. Miliken ST, Powles RL. Antifungal prophylaxis in bone marrow transplantation. Rev Infect Dis 1990; 12: 374-379.
66. Wiesner RH, Hermans PE, Rakela J, Washington JA, Perkins JD, DiCecco S et al. Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation 1988; 45: 570-574.
67. Gombert ME, du Bouchet L, Aulicino TM, Butt KMH. A comparative trial of clotrimazole troches and oral nystatin suspension in recipients of renal transplantation: use in prophylaxis of oropharyngeal candidiasis. JAMA 1987; 258: 2.553-2.555.
68. Schmitt HJ, Bernard EM, Hauser M, Armstrong D. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1988; 32: 1.676-1.679.
69. Conneally E, Caffrekey MT, Daly PA, Keane CT McCann SR. Nebulized amphotericin B as a prophylaxis against invasive aspergillosis in granulocytopenic patients. Bone Marrow Transplant 1990; 5: 403-406.
70. Gavaldà J, Román A, Bravo C, Almirante B, Pigrau C, Pahissa A et al. Profilaxis con amfotericina B nebulizada y ganciclovir en pacientes con trasplante pulmonar [resumen 133]. VI Congreso Nacional de la SEIMC. Valencia, 1994.
71. Meyer RD. Current role of therapy with amphotericin B. Clin Infect Dis 1992; 14 (Supl 1): 154-160.
72. Terrell CT, Hughes CE. Antifungal agents used for deep-stated mycotic infections. Mayo Clin Proc 1992; 67: 69-91.
73. Mora NP, Klintmalm G, Solomon H, Goldstein RM, Gonwa TA, Husberg BC. Selective amphotericin prophylaxis in the reduction of fungal infections after liver transplant. Transplant Proc 1992; 24: 154-155.
74. Nieto-Rodríguez JA, Kusne S, Máñez R, Starzl TE, Iwatsuki T, Green M et al. Factors associated with the development of candidemia and candidemia-related death among liver transplant recipients. Ann Surg 1996; 223: 70-76.
75. Singh N, Mieles L, Yu VL, Gayowski T. Invasive aspergillosis in liver transplant recipients: association with candidemia and conssumption coagulopathy and failure with low-dose amphotericin B. Clin Infect Dis 1993; 17: 906-908.
76. De Marie S, Janknegt R, Bakker-Woudenberg IA. Clinical use of liposomal and lipid-complexed amphotericin B. J Antimicrob Chemother 1994; 33: 907-916.
77. Berenguer J, Muñoz P, Parras F, Fernández-Baca V, Hernández-Sampelayo T, Bouza E. Treatment of deep mycoses with liposomal amphotericin B. Eur J Clin Microbiol Infect Dis 1994; 13: 136-140.
78. Ringden O, Andstrom E, Remberger B, Svahn M, Tollemar J. Safety of liposomal amphotericin B (Ambisome) in 187 transplant patients treated with cyclosporine. Bone Marrow Transplant 1994; 14 (Supl 5): 10-14.
79. Tollemar J, Hockerstedt K, Ericzon BG, Jalanko H, Ringden O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. Transplantation 1995; 59: 45-50.
80. Saag MS, Dismukes WE. Azole antifungal agents. Emphasis on new triazoles. Antimicrob Agents Chemother 1988; 32: 1-2.
81. López-Gil JA. Fluconazole-cyclosporine interaction: a dose dependent effect. Ann Pharmacother 1993; 27: 427-430.
82. Slavin MA, Osborne B, Adams R, Levenstein MJ, Scoch HG, Feldman AR et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double blind study. J Infect Dis 1995; 171: 1.545-1.552.
83. Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, multicenter trial. Ann Intern Med 1993; 118: 495-503.
84. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R. Increase incandida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1.274-1.277.
85. Menichetti F, Del Favero A, Martino P, Bucaneve G, Micozzi A, D'Antonio D et al. Preventing fungal infection in neutropenic patients with acute leukemia: fluconazole compared with oral amphotericin B. Ann Intern Med 1994; 120: 913-918.
86. Lumbreras C, Cuervas-Mons V, Jara P, Del Palacio A, Turrión VS, Barrios C et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996; 174: 583-588.
87. Hibberd PL, Rubin PH. Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis 1993; 19 (Supl 1): 33-49.
88. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetics properties and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-344.
89. Kwan JTC, Foxall PJD, Davidson DGC, Bending MR, Eisinger AJ. Interaction of cyclosporine and itraconazole. Lancet 1987; 2: 282-283.
90. Novakova I, Donnelly P, De Witte T, De Pauw B, Boezeman J, Veltman G et al. Itraconazole and cyclosporine nephrotoxicity. Lancet 1987; 2: 290.
91. Muñoz P, Bouza E, Prevención y tratamiento de las infecciones fúngicas en receptores de trasplante de órgano sólido. Rev Clin Esp 1995; 195 (Supl 3): 38-48.
92. Kusne S, Torre-Cisneros J, Máñez R, Irish W, Martin M, Fung J. Factors associated with invasive lung aspergillosis and the significance of positive aspergillus culture after liver transplantation. J Infect Dis 1992; 166: 1.379-1.383.
93. Stratta RJ, Shaeffer MS, Markin RS, Wood RP, Langnas AN, Reed EC et al. Cytomegalovirus infection and disease after liver transplantation. An overviews. Dig Dis Sci 1992; 37: 673-688.
94. Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin EN. Infection in the renal transplant recipient. Am J Med 1981; 70: 405-411.
95. Payá CV, Hermans PE. Bacterial infections after liver transplantation. Eur J Microbiol Infect Dis 1989; 8: 499-504.
96. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 1989; 261: 3.607-3.609.
97. Wiesner RH, Marin E, Porayko MK, Steers JL, Krom RA, Paya CV. Advances in the diagnosis, treatment, and prevention of cytomegalovirus infections after liver transplantation. Gastroenterol Clin North Am 1993; 22: 351-366.
98. Fox AS, Tulpin MD, Baker AL, Broechsl CE, Whittington PF, Jackson T et al. Seropositivity in liver transplant recipients as a predictor of cytomegalovirus disease. J Infect Dis 1988; 157: 383-387.
99. Patel R, Snydman DR, Rubin RH, Ho M, Pescovitz M, Martin M, Payá CV. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1.279-1.289.
100. Sayers MH, Anderson KC, Goodnough LT, Kurtz SR, Lane TA, Pisciotto et al. Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med 1992; 116: 55-62.
101. Lang DJ, Ebert PA, Rodgers BM, Mittchell RF, Douglas M, Turner K et al. Reduction of post-transfusion cytomegalovirus infections following the use of leukocyte depleted blood. Transfusion 1977; 17: 391-395.
102. Plotkin SA. Cytomegalovirus vaccine development. Past and present. Transplant Proc 1991; 23: 85-89.
103. Plotkin SA, Starr SE, Friedman HM, Goczol E, Brayman K. Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis 1990; 12: 827-838.
104. Plotkin SA, Starr SE, Friedman HM, Brayman S, Harris S, Jackson S et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. Ann Intern Med 1991; 114: 525-531.
105. Brit W, Fay J, Seals J, Kensil C. Formulation of a immunogenic human cytomegalovirus vaccine: responses in mice. J Infect Dis 1995; 171: 18-25.
106. Snydman DR, Werner BG, Heinze-Lacey B, Verardi VP, Tilney NL, Kirkman RL et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients. N Engl J Med 1987; 317: 1.049-1.054.
107. Kaisike BL, Heim-Duthoy KL, Tortorice KL, Ney AL, Odlane MD, Venkateswara K. Polyvalent immune globulin and cytomegalovirus infection after renal transplantation. Arch Intern Med 1989; 149: 2.733-2.777.
108. Cofer JB, Morris CA, Sutker WL, Husberg BS, Goldstein TA, Gonwa TA et al. A randomized double-blind study of the effect of prophylactic immune globulin on the incidence and severity of CMV infection in the liver transplant recipient. Transplant Proc 1991; 23: 1.525-1.529.
109. Greger B, Vallbracht A, Kurth J, Shaerek WD, Muller GH, Hopt UT et al. The clinical value of CMV prophylaxis by CMV hyperimmune serum in kidney transplant patients. Transplant Proc 1986; 18: 1.387-1.392.
110. Glowacki LS, Smaill FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients: a meta-analysis. Clin Transplant 1994; 8: 10-18.
111. Patel R, Snydman DR, Rubin RH, Ho M, Pescovitz M, Martin M, Payá CV. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996; 61: 1.279-1.289.
112. Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, Vicary CA et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogenic marrow transplantation. N Engl J Med 1988; 318: 70-75.
113. Prentice HG, Glauckman E, Powles RL, Ljungman P, Milpied NJ, Fernández-Rañada JM, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogenic bone marrow transplantation. Lancet 1994; 343: 749-753.
114. Balfour HH, Chace BA, Stapleton JT, Simmons RL, Fryd DS. A randomized, placebo controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal grafts. N Engl J Med 1989; 320: 1.381-1.387.
115. Bailey TC, Ettinger NA, Storch GA, Cooper JD, Powderly WG. Failure of high-dose oral acyclovir with or without globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med 1993; 95: 273-277.
116. Winston D, Wirin D, Shaked A, Busutil R. Randomised comparison of ganciclovir and high-dose acyclovir of long-term cytomegalovirus prophylaxis in liver transplant recipients. Lancet 1995; 346: 69-74.
117. Mollison LC, Richards MJ, Johnson PDR, Hayes K, Munckof WJ, Jones RM et al. High-dose acyclovir reduces the incidence of cytomegalovirus infection in liver transplant recipients. J Infect Dis 1993; 168: 721-724.
118. Rondeau E, Bourgeon B, Peraldi MN. Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients. Nephrol Dial Transplant 1993; 8: 858-862.
119. Martin M, Mañez R, Linden P. A randomized controlled trial comparing oral high dose acyclovir to ganciclovir for the prevention of cytomegalovirus infection in adult liver transplant recipients. Transplantation 1994; 58: 779-784.
120. Cohen AT, O'Grady JG, Sutherland S, Sallie R, Tan K-C, Williams R. Controlled trial of prophylactic versus therapeutic use of ganciclovir in liver transplantation in adults. J Med Virol 1993; 40: 5-10.
121. Merigan TC, Renlund DG, Keay S, Bristow MR, Starnes V, O'Connell JB et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 1992; 326: 1.182-1.186.
122. Aguado JM, Gómez-Sánchez MA, Lumbreras C, Delgado J, Otero JR, Rufilanchas JJ et al. Prospective randomized trial of efficacy versus that of anti-cytomegalovirus immunoglobulin to prevent CMV disease in CMV seropositive heart transplant recipients treated OKT3. Antimicrob Agents Chemother 1995; 39: 1.643-1.645.
123. Duncan SR, Grgurich WF, Iacono AT, Burckart GJ, Yousem SA, Paradis IL et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994; 150: 146-152.
124. Bailey TC, Trulock EP, Ettinger NA, Storch GA, Cooper JD, Powderly WG. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis 1992; 165: 548-552.
125. Kelly JL, Albert RK, Wood DE, Raghu G. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients. Transplantation 1995; 59: 1.144-1.147.
126. Hibberd PL, Tolkoff-Rubin NE, Conti D, Cosimi AB, Schooley RT, Isaacson D et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Interm Med 1995; 123: 18-23.
127. Lumbreras C, Otero JR, Herrero JA, Gómez R, Lizasoain M, Aguado JM et al. Ganciclovir prophylaxis decreses frequency and severity of cytomegalovirus disease in seropositive liver transplant recipients treated with OKT3 monoclonal antibodies. Antimicrob Agents Chemother 1993; 37: 2.490-2.492.
128. Winston DJ, Imagawa DK, Holt CD, Kaldas F, Shaked A, Busutil RW. Longt-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. Transplantation 1995; 60: 1.357-1.360.
129. Hopt UT, Pfeffer F, Schareck W, Busing M, Ming C. Ganciclovir for prophylaxis of CMV disease after pancreas/kidney transplantation. Transplant Proc 1994; 26: 434-435.
130. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High-dose acyclovir compared with short-course preemptive ganciclovir therapy to prevent cyomegalovirus disease in liver transplant recipients. A randomized trial. Ann Intern Med 1994; 120: 375-379.
131. Conti DJ, Freed BM, Singh TP, Gallichio M, Gruber SA, Lempert N. Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients. Arch Surg 1995; 130: 1.217-1.222.
132. Grossi P, Kusne S, Rinaldo CH, St George K, Magnone M, Rakela J et al. Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors. Transplantation 1996; 61: 1.959-1.960.
133. Zaia JA, Forman SJ. Cytomegalovirus infection in the bone marrow transplant recipient. Infect Dis Clin North Amer 1995; 9: 879-895.
134. Polis MA, Spooner KM, Baird BF, Manischewitz JF. Anticytomegaloviral activity and safety of cidofovir in opatients with human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother 1995; 39: 882-886.
135. Kirsch LS, Arévalo JF, Chávez de La Paz E, Munguía D, De Clercq E, Freeman WR. Intravitreal cidofovir treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophtalmology 1995; 102: 533-543.
136. Winston DJ. Prevention of cytomegalovirus disease in transplant patients. Lancet 1995; 346: 1.380-1.381.
137. Singh N, Dummer JS, Kusne S, Breinig MK, Armstrong JA, Makowka L et al. Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis 1988; 158: 124-131.
138. Kusne S, Schwartz M, Breining MK, Dummer JS, Lee RE, Selby R et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis 1991; 163; 1.001-1.007.
139. Patti ME, Selvaggi KJ, Kroboth FJ. Varicella hepatitis in the imunocompromised adult: a case report and review of the literature. Am J Med 1990; 88: 77-82.
140. Kusne S, Pappo O, Máñez R, Pazin G, Carpenter B, Fung JJ et al. Varicella-zoster virus hepatitis and a suggested management plan for prevention of VZV infection in adult liver transplant recipients. Transplantation 1995; 60: 619-621.
141. McGregor RS, Zitelli BJ, Urbach AH, Malatack JJ, Gartner JC. Varicella in pediatric orthotopic liver transplant recipients. Pediatrics 1989; 83: 256-260.
142. Gershon AA. Human immune responses to VZV live attenuated vaccine. Rev Infect Dis 1991; 13 (Supl 13): 957-962.
143. Wagner HJ, Bein G, Bitsch A, Kirchner H. Detection and quantitation of latently infected B-lymphocites in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microb 1992; 30: 2.826-2.829.
144. Walker RC, Paya CV, Marshall WF, Strickler JG, Wiesner RH, Velosa JA et al. Pretransplantation seronegative Epstein-Barr virus status in the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantation. J Heart Lung Transplant 1995; 14: 214-221.
145. Kuo PC, Dafoe DC, Alfrey EJ, Sibley RK, Scandling JD. Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis. Transplantation 1995; 59: 135-140.
146. Sable CA, Hayden FG. Orthomyxoviral and paramyxoviral infections in transplant patients. Infect Dis Clin North Am 1995; 9: 863-879.
147. Ljungman P, Anderson J, Aschan J, Barkholt L, Ehrnst A, Johansson M et al. Influenza A in imunocompromised patients. Clin Infect Dis 1993; 17: 244-247.
148. Kumar SS, Ventura AK, Vander Werf B. Influenza vaccination in renal transplant recipients. JAMA 1978; 239: 240-242.
149. Blumberg EA, Albano C, Pruett T, Issacs R, Fitzpatrick J, Bergin J et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996; 22: 295-302.
150. Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin North Am 1995; 9: 1.005-1.044.
151. Hennequin C, Page B, Roux P, Legendre C, Kreis H. Outbreak of Pneumocystis carinii pneumonia in a renal transplant unit. Eur J Clin Microbiol Infect Dis 1995; 14: 122-126.
152. Moreno A, Rimola A, Claramonte J, Andreu H, Navasa M, Cirera I. Eficacia de cotrimixazol en la profilaxis de la neumonia por Pneumocystis carinii en el trasplante hepático [resumen 26/14]. VII Congreso de la SEIMC. Torremolinos, 1996.
153. Muñoz P, Muñoz R, Palomo J, Pelaez T, Alonso R, Bouza E. Neumonía por Pneumocystis carinii en el trasplantado cardiaco. Utilidad de la profilaxis con cotrimoxazol dos dias por semana [resumen 26/13]. VII Congreso de la SEIMC. Torremolinos, 1996.
154. Torre-Cisneros J, Villanueva JL, Fraga I, Rufian S, Kindelan JM, Pera C. A prospective randomized trial comparing fansidar and cotrimoxazol in prevention of Pneumocystis carinii pneumonia after liver transplantation [resumen 1146]. 6th European Congress of Clinical Microbiology and Infectious Diseases. Sevilla, 1993.
155. Hakim M. Toxoplasmosis in cardiac transplantation. BMJ 1986; 92: 1.108.
156. Ryning FW, McLeod R, Madox JC. Probable trasmission of Toxoplasma gondii by organ transplantation. Ann Intern Med 1979; 84: 47-49.